Evidence map›Paper›PMID 38464207›Full record

ArticleResearch square2024

Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease.

Kavya Prasad, Brian E Serencsits, Bae P Chu, Lawrence T Dauer, Maria Donzelli, Ellen Basu, Kim Kramer, Neeta Pandit-Taskar

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kavya PrasadMemorial Sloan Kettering Cancer Center.
Brian E SerencsitsMemorial Sloan Kettering Cancer Center.
Bae P ChuMemorial Sloan Kettering Cancer Center.
Lawrence T DauerMemorial Sloan Kettering Cancer Center.
Maria DonzelliMemorial Sloan Kettering Cancer Center.
Ellen BasuMemorial Sloan Kettering Cancer Center.
Kim KramerMemorial Sloan Kettering Cancer Center.
Neeta Pandit-TaskarMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-1551-2036
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Treating CNS malignancies with 131-I-8H9R21CA117076 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI KRAMER, KIM · 2005 to 2006
$699k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA117076
6 · The paper itself

Abstract

Background: Radiolabeled antibody Methods: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of Results: Post-administration exposure rates for patients ranged from 0.16-0.46 μSv/hr/MBq at 1 ft and 0.03-0.08 μSv/hr/MBq at 1 m. Radiation exposure duration ranged from 1-10 days after release for the four evaluated cohorts. Based on the highest measured exposure rates and slowest whole-body clearance, the longest precautions were approximately 78% lower than the regulatory guidance recommendations. Radiation exposure to staff associated with Conclusion:

Indexed as

Brain metastasesradiation safetyradiopharmaceutical

Identifiers

PMID38464207
PMCPMC10925439
OpenAlexW4392230599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.